Clinical trials: Embryonal Neoplasm
Malignant Melanoma
Study of a DNA Immunotherapy to Treat Melanoma
The study is an investigation of a novel immunotherapy, SCIB1, for the treatment of melanoma. SCIB1 is a solution of plasmid DNA molecules which will express a modified antibody in human cells.
- Trial name
- NCT01138410
- Testing
- SCIB1
- Where
- 5 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Scancell Ltd
Metastatic Melanoma
Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells
This protocol was conducted as a single institution trial at Hoag Cancer Center, Hoag Hospital, Newport Beach, California. It was a single-arm phase II trial in which patients with metastatic melanoma received subcutaneous (s.c.)…
- Trial name
- DCVaccineMel (NCT00948480)
- Testing
- Autologous tumor cells plus dendritic cells, GM-CSF
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors.
- Conditions
- Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma
- Trial name
- NCT01837862
- Testing
- Mebendazole, Vincristine, Carboplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Julie Krystal
Melanoma, Ovarian Cancer
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
This protocol is to provide follow-up medical/surgical visits for DCS patients who are long term survivors and may not currently be a participant entered on an active research protocol.
- Conditions
- Melanoma, Ovarian Cancer, Prostate Cancer, Breast Cancer
- Trial name
- NCT00001503
- Where
- United States
- Volunteers
- 1,031 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma Stage IV, Melanoma Stage III
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
This is a Phase 1/2, open label, multi-centre study to assess the safety, tolerability, PD, and efficacy of adjuvant immunotherapy EVX-02 vaccine and anti-PD-1 (Nivolumab) in patients who have had a complete resection of a Stage…
- Trial name
- NCT04455503
- Testing
- EVX-02A, EVX-02B, EVX-02A OR EVX-02B
- Where
- 6 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Evaxion Biotech A/S
Stage IV Skin Melanoma
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
This pilot clinical trial studies aldesleukin imaging in viewing tumor growth in patients with stage IV melanoma receiving ipilimumab or pembrolizumab therapy.
- Trial name
- NCT01789827
- Testing
- Laboratory Biomarker Analysis, Radionuclide Imaging, Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Uveal Melanoma
Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external radiotherapy) patients with high risk of metastasis are randomized between: Adjuvant chemotherapy with Fotemustin.
- Trial name
- FOTEADJ (NCT02843386)
- Testing
- Adjuvant chemotherapy by Fotemustin, Intensive surveillance
- Where
- 6 sites in France, Switzerland
- Volunteers
- 302 people
- Sponsor
- Institut Curie
ALK-activated Tumors
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose…
- Trial name
- NCT01742286
- Testing
- Ceritinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Melanoma
Nab-PCE vs PC for MM After Failure of Anti-PD-1
This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin Endostatin for advanced melanoma after failure of PD-1 therapy.
- Trial name
- NCT03917069
- Testing
- Chemotherapeutic Combinations, chemotherapy
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Peking University Cancer Hospital & Institute
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer
- Trial name
- NCT00007813
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma (Skin)
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
This is a pilot phase 1, open-label, single center, multi-dose, dose-escalation study of BMS-936558 in combination with or without a peptide vaccine.
- Trial name
- NCT01176461
- Testing
- MART-1, NY-ESO-1, gp100:209-217(210M)
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Sarcoma
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
RATIONALE: Giving chemotherapy drugs, such as busulfan, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of tumor cells and prepares the patient's bone marrow for the stem cells.
- Trial name
- NCT00357396
- Testing
- graft versus host disease prophylaxis/therapy, busulfan, melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Recurrent Glioblastoma
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable).
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Resectable Glioblastoma
- Trial name
- NCT06090903
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Medical Chart Review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
GBM, Glioma Glioblastoma Multiforme
WBSI Guided Personalized Delivery of TTFields
This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that utilizes - tumor treating fields (TTFields), (aka, electrical therapy), which has…
- Conditions
- GBM, Glioma Glioblastoma Multiforme, Tumor, Brain
- Trial name
- NCT05086497
- Testing
- Whole Brain Spectroscopy Imaging Array Mapping Layout
- Where
- 2 sites in United States
- Volunteers
- 155 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Soft-tissue Sarcoma, Osteosarcoma
Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.
Non-randomized, open, two-cohort, phase II, multicenter national clinical trial. 20 sites in Spain. Cohort 1 includes soft-tissue sarcoma and osteosarcoma (21 patients), while Cohort 2 includes chordoma patients only (19…
- Conditions
- Soft-tissue Sarcoma, Osteosarcoma, Chordoma
- Trial name
- PalboSarc (NCT03242382)
- Testing
- Palbociclib
- Where
- 19 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Brain and Central Nervous System Tumors
Fenretinide in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent…
- Trial name
- NCT00006080
- Testing
- fenretinide
- Where
- 11 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma
Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
This phase 1/2 trial addresses the efficacy and safety of the combination of dabrafenib, trametinib and the oral autophagy inhibitor hydroxychloroquine in patients with unresectable AJCC (American Joint Committee on Cancer) stage…
- Trial name
- COMBI-R2 (NCT03754179)
- Testing
- Dabrafenib, Trametinib, Hydroxychloroquine
- Where
- Belgium
- Volunteers
- 63 people
- Sponsor
- Universitair Ziekenhuis Brussel
Unresectable or Metastatic Melanoma
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
- Trial name
- NCT01721746
- Testing
- BMS-936558, Dacarbazine, Carboplatin
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 405 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrades arginine. ADI has been formulated with polyethylene glycol, and has been used to treat patients that have cancers…
- Trial name
- NCT01665183
- Testing
- ADI-PEG 20
- Where
- 2 sites in United States, Taiwan
- Volunteers
- 8 people
- Sponsor
- Polaris Group
Breast Carcinoma, Carcinoma of Unknown Primary
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver…
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma
- Trial name
- NCT01366144
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.